Introduction
Angiogenesis is essential for the growth of both primary and metastatic tumors, and the understanding of the mechanism involved in angiogenic dysregulation could lead to the development of antiangiogenic therapies (Folkman et al., 1989) . Tumor angiogenesis involves several processes, including endothelial cell (EC) activation, proliferation, migration and tissue infiltration from preexisting blood vessels that are triggered by specific angiogenic growth factors produced by tumor cells and the surrounding stroma (Hanahan and Folkman, 1996) . Several growth factors, such as vascular endothelial growth factor (VEGF) (Alon et al., 1995) , basic fibroblast growth factor (Javerzat et al., 2002) and angiopoietin (Kwak et al., 1999) , have been identified as possible regulators of angiogenesis. These factors have been shown to physically bind and activate receptor tyrosine kinases, thereby initiating intracellular signaling, which drive the angiogenic process.
Osteopontin (OPN) is a phosphorylated acidic RGDcontaining glycoprotein that binds certain CD44 variants and integrin receptors, including a v b 3 (Denhardt et al., 2001) . OPN acts as a cytokine that plays important roles in colony formation, migration and invasion of tumor cells (Rittling and Chambers, 2004; Tuck et al., 2007) . On the other hand, OPN is regarded to be an important angiogenic factor in tumor angiogenesis. Previous studies suggest that co-expression of OPN and VEGF is closely associated with angiogenesis and poor prognosis in lung adenocarcinoma (Shijubo et al., 2003) . VEGF augments OPN and avb3-integrin expression in human umbilical vein endothelial cell (HUVEC) and stimulates integrindependent EC motility (Senger et al., 1996) . Recently, it is reported that OPN increased VEGF expression in tumor cells stimulating neovascularization. In turn, VEGF also induced the overexpression of OPN in tumor cells. (Chakraborty et al., 2008) . Thus, experimental evidence suggests that OPN may affect angiogenesis by acting directly on ECs. However, OPN's direct effects on HUVEC and the signaling molecules inside HUVEC activated by OPN are poorly defined.
Several pathways are shown to be involved in the angiogenesis process induced by the angiogenic growth factors. Phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT/PKB) pathway is an important signal molecule associated with EC survival and migration induced by VEGF and basic fibroblast growth factor. (Gerber et al., 1998; Shiojima and Walsh, 2002) . Once it is activated, AKT can promote cell survival through activation of the nuclear factor (NF)-kB (Beraud et al., 1999; Kane et al., 1999) and upregulation of the expression of the antiapoptotic protein Bcl-2, by which growth factors induce cell survival (Pugazhenthi et al., 2000) . Relative activity factor/mitogen-induced extracellular kinase/extracellular signal-regulated kinase (ERK) pathway activated by VEGF and FGF has also been implicated in the regulation of cell motility and survival (Wu et al., 2000, L'Hoˆte and Knowles, 2005) . However, molecular mechanisms by which OPN regulates EC migration and tube formation are poorly understood.
In this study, we unveiled the angiogenic activities of OPN, including promotion of proliferation, migration and capillary tube formation of HUVECs in vitro, and induction of neovascularization in chick chorioallantoic membrane (CAM), rabbit corneal micropocket and MCF-7 xenograft tumor angiogenesis model in vivo. The signaling pathways involved in angiogenesis mediated by OPN were also investigated.
Results

OPN induces HUVEC proliferation, survival, migration and tube formation
To determine whether OPN directly affects the viability of primary ECs, we investigated the effect of OPN on proliferation and apoptosis of HUVECs. In the presence of OPN, 3 H-thymidine uptake of HUVECs increased 3.08±0.64 fold (Figure 1a , Po0.01) and, however, this incorporation uptake decreased 2.76 ± 0.35 fold when anti-OPN antibody 1A12 was added. FACScan analysis showed that the exogenous soluble OPN protected HUVECs from serum deprivation-induced apoptosis from 23.96 to 2.39%. Treated with 1A12 increased the apoptotic rate of HUVECs from 2.89 to 19.86% (Figure 1b) . Our results showed that OPN might support EC survival under conditions that had been shown to induce HUVEC apoptosis.
In a haptotactic migration assay, only a few control cells (bovine serum albumin-coated insert) were found in the lower chamber, whereas more than 40-fold increment of the migrated cells could be detected if OPN was coated on the lower surface of filter membrane as a haptotaxic agent (Figure 1c ). Anti-OPN antibody 1A12 inhibited OPNinduced cell migration by 80%, indicating that OPN is important in promoting HUVEC migration.
Human umbilical vein endothelial cells completely reorganize when cultured with complete medium in three-dimensional matrigel and finally form a network of tubular structures with multiple cell-cell contacts (Figure 1d ). The same effect was also observed when only OPN was added. This OPN-induced tube formation was inhibited by incubation with anti-OPN antibody 1A12. These results suggest that OPN-EC interaction is sufficient to promote EC proliferation, migration and tube formation.
OPN sustains the survival of endothelia cells through the avb3-mediated PI3K/AKT and ERK pathway To determine the signal-transduction pathways in OPNtreated ECs, we first investigate the expression of CD44 and avb3 on HUVECs by flow cytometry analysis. Figure 2a shows that the expression of CD44 is extremely low, whereas integrin-avb3 is highly expressed on the surface of HUVECs. Then, the phosphorylation of PI3K, AKT and ERK1/2 were examined. PI3K activation was observed at 15 min with a peak at 30 min and decreasing to near basal levels in 1 h when HUVECs were grown with OPN ( Figure 2b ). After HUVECs exposure to OPN for 4 h, PI3K was phosphorylated again and lasted for 24 h. The OPN-induced phosphorylation of PI3K was also dose-dependent after 30 min of treatment (Figure 2c ). The time course of phosphorylation of AKT and ERK1/2 was almost the same as the PI3K. A concentration-dependent effect of OPN on HUVECs in causing Akt and ERK1/2 phosphorylation can also be observed. We further determined whether the activation of Akt and ERK pathways in HUVECs was avb3-dependent. As shown in Figure 2d , anti-avb3 antibody abrogated the activation of the AKT and ERK1/2 pathway just as anti-OPN antibody 1A12 did, whereas anti-CD44 antibody had no effect on HUVECs. Furthermore, we show that OPN induces the expression of Bcl-xL through activation of the PI3K pathway but not the mitogen-induced extracellular kinase/ERK pathway in HUVEC following serum withdrawal (Supplementary Figure 1a) . In addition, we found that PI3K is required for OPN-induced activation of NF-kB in ECs (Supplementary Figure 1b) .
OPN increases the synthesis of VEGF and phosphorylation of KDR in a dose-and time-dependent manner through the AKT and ERK pathway To determine whether autocrine factors released by HUVECs after OPN stimulation were associated with the second phase activation of PI3K and ERK, we first analysed expression of VEGF in HUVECs treated with OPN by real-time reverse transcription-PCR. As shown in Figure 3a , OPN increased VEGF expression in a dose-dependent manner. Incubation of HUVECs with OPN resulted in greater than fivefold increases in the relative level of VEGF. VEGF mRNA levels were increased substantially by 4 h and relatively high levels persisted for 24 h after stimulation with OPN ( Figure 3b) . In addition, we tested VEGF expression and the phosphorylation level of KDR by western blot. The phosphorylation of KDR is correlated with the level of VEGF expression (Figure 3c ). Furthermore, we found that OPN-induced VEGF was significantly inhibited by LY294002 together with PD98059. Single pathway inhibitor could partially reduce VEGF expression (Figure 3d ). These data indicate that both the AKT and ERK pathway might have an important function upstream in OPN-induced VEGF expression in HUVECs. Complete expression inhibition was observed in the group treated with anti-avb3 antibody. Anti-VEGF antibody had no inhibition effect on VEGF expression. These findings suggest that OPN induces VEGF expression through interacting with integrinavb3 and activating downstream the PI3K/AKT and ERK pathway.
VEGF feedback signal is involved in the secondary phase activation of the AKT and ERK pathway It was reported that AKT and ERK pathways are also the downstream effectors of KDR (also called VEGFR-2), which is highly expressed on the surface of HUVECs (Kilic et al., 2006) . Thus it is possible that VEGF is involved in the secondary phase activation of the AKT and ERK pathway. To validate this hypothesis, phosphorylation of AKT and ERK were detected at 30 min and 24 h after treatment, respectively. The primary phase of OPN in causing ERK1/2 and Akt phosphorylation was not affected by anti-VEGF antibody as compared with the control (Figures 4a and b) , but the secondary delayed phase of OPN in causing ERK and AKT phosphorylation was reduced ( Figures  4c and d) . In addition, we found that the phosphorylation of AKT and ERK was abolished by pretreatment of anti-OPN antibody in the early time phase (30 min). 
Blockage of the feedback pathway inhibits the viability of HUVECs
Human umbilical vein endothelial cell proliferation is inhibited over 75% by blocking AKT/ERK pathways with the treatment of LY294002 and PD980592 or anti-avb3 antibody ( Figure 5a ). Single pathway inhibitor reduced the cell proliferation by about 44-48%, whereas anti-VEGF antibody could only inhibit OPN-induced cell proliferation by 24%. Similar results were observed in the cell migration and tube formation assay (Figures 5b and c) . Anti-OPN or anti-avb3 antibody almost completely blocked the migration and tube formation of HUVECs induced by OPN. We also compared the blocking effects of anti-VEGF and anti-OPN antibodies in a higher (100 mg/ml) or lower concentration (4 mg/ml). Anti-OPN antibody worked better than anti-VEGF antibody (data not shown). In addition, we found that OPN-induced migration and tube formation was significantly inhibited by LY294002 in together with PD98059. Single pathway inhibitor had only partial inhibition effects. These data show that VEGF signal is involved in the OPN-induced EC proliferation and motility. AKT/ERK pathways, which are activated by OPN and re-stimulated by VEGF, are critical for OPN-induced migration and tube formation of HUVECs.
Anti-OPN antibody 1A12 inhibits angiogenesis in CAM and corneal pocket model
To determine the angiogenic potential of OPN in vivo, we explore whether local administration of OPN has angiogenic activity using two well-defined in vivo angiogenesis system. As shown in Figure 6a , OPN induced a strong angiogenic response in the CAM, similar to that of VEGF. 1A12 antibody showed a strong antiangiogenic effect in the CAM assay. Few blood vessels penetrated into the region where 1A12 antibody was applied. In contrast, anti-VEGF antibody could only partially inhibit the angiogenesis induced by OPN. In OPN-induced rabbit corneal neovascularization model (Figure 6b ), control pellets with phosphatebuffered saline alone did not induce an angiogenic response. Implants containing VEGF and OPN induced corneal neovascularization. In the presence of anti-OPN antibody 1A12, angiogenesis toward OPN was significantly inhibited. Implants containing OPN plus anti-VEGF antibody still gave partially positive response. These findings show that anti-OPN 1A12 antibody had 6 cells) were cultured in the presence or absence of OPN (5 mM) for various times or (c) in the presence of various concentrations of OPN for 30 min, and then lysed with lysis buffer. After immunoprecipitation (IP) of PI3K p85, cell lysates were applied to SDS-polyacrylamide gel electrophoresis (8%). Tyrosine-phosphorylated proteins were detected by western blotting (WB) using anti-phosphotyrosine antibody coupled with ECL, and then re-probed with polyclonal antibody (pAb) against PI3K p85. AKT or ERK1/2 activation was detected by western blotting using anti-pAKT pAb or anti-pERK mAb coupled with ECL, whereas level of AKT and ERK was used as an internal control. (d) HUVECs were cultured in 5 mM of OPN with or without the treatment of anti-OPN, anti-CD44 and anti-avb3 for 30 min, and then lysed with lysis buffer. Western blotting was used to measure the tyrosine phosphorylation of AKT and ERK1/2. The pattern shown is a representative one of three similar results.
better inhibitory function toward angiogenesis induced by OPN than anti-VEGF did in vivo.
Anti-OPN antibody 1A12 impairs OPN-induced new vessel formation in MCF-7 xenografts through the induction of apoptosis of ECs To determine the angiogenic potential of OPN on breast tumors, we next determined whether blockade of OPN by antibodies could result in suppressing neovascularization of OPN-transfected MCF-7 xenografts in nude mice. As shown in Figure 6c , overexpression of OPN significantly increased the microvessel density (MVD) in MCF-7 tumors. Moreover, treatment with anti-OPN or anti-VEGF antibody decreased the MVD dramatically. Furthermore, the EC marker CD31 identified a significantly lower MVD in sections of anti-OPN 1A12-treated MCF-7 tumors than anti-VEGF-treated MCF-7 tumors. (1A12-treated MCF-7 tumors ¼ 4.33 vessels/ mm 2 versus anti-VEGF-treated MCF-7 ¼ 6.54 vessels/ mm 2 ; difference ¼ 0.67 vessels/mm 2 , Po0.05; Figure 6c ). Immunofluorescent double staining for CD31 and terminal deoxynucleotidyl transferase-mediated nick end labeling showed that the ECs undergoing apoptosis (yellow staining in Figure 6d) were observed in the anti-OPN or anti-VEGF antibody-treated group. Apoptotic ECs were not identified in tumors from control IgGtreated mice. These results indicate that OPN can induce angiogenesis in MCF-7 xenografts in vivo, and anti-OPN antibody can block its effects through directly inducing the apoptosis of ECs.
Discussion
Overexpression of OPN has been shown to regulate tumor metastasis and angiogenesis, and the avb3-integrin has been implicated in this process (Denhardt and Chambers, 1994; Denhardt, 1996; Standal et al., 2004) . However, the molecular mechanisms remain to be elucidated and, most importantly, it is not clear whether OPN-induced signaling in endothelium directly contributes to tumor angiogenesis. In this study, our data indicate that OPN confers cytoprotection through the activation of the PI3K/Akt pathway with subsequent upregulation of Bcl-xL and activation of NF-kB. In addition, OPN enhanced the expression of VEGF and increased the activation of KDR through phosphorylation of AKT and ERK. Furthermore, OPNinduced VEGF activates the PI3K/AKT and ERK1/2 pathway as a positive feedback signal. Blocking the Osteopontin induces HUVEC angiogenesis J Dai et al feedback signal by anti-VEGF can only partially inhibit the OPN-induced EC motility, proliferation and tube formation, whereas blocking the signal by anti-OPN or anti-avb3 almost completely abrogated the effects of OPN on HUVECs. In CAM, rabbit corneal micropocket model and MCF-7 xenograft model, the antiangiogenesis effect of anti-OPN antibody, which blocks both of these two signal pathways, is more effective than that of anti-VEGF antibody, which can only block the feedback signals. We show that OPN directly induces tumor angiogenesis by the activation of PI3K/AKT and ERK1/2 pathway in ECs with VEGF acting as a positive feedback signal. Osteopontin is a multifunctional cytokine that has important functions in cell survival and migration. The signaling pathways that involved in its functions appear to vary in different cell types. In osteoclast precursors, RANKL activates Akt survival signaling pathway and the OPN-stimulated cell migration (Toshifumi et al., 2003) . In prostate cancer, PKCa/c-Src/IKK/ NF-kB signaling cascades lead to OPN-induced tumor cell migration and EC motility (Jain et al., 2006) . In breast cancer cells, PI3-kinase phosphorylation has been shown to be induced by OPN (Das et al., 2003) . MAPKs/ERK/AP-1-mediated signaling pathways are associated with OPN-induced lymphocyte migration and motility (Cao et al., 2008) . The signal pathways in endothelia cells induced by OPN are not fully defined. In this study, Akt was activated after OPN treatment and this effect persisted for at least 24 h, suggesting that Akt activation might be related to OPN-induced cell proliferation. In addition, OPN induces ERK1/2 phosphorylation in a concentration-dependent manner. Anti-OPN antibody inhibited not only the activation of PI3K/AKT but also the phosphorylation of ERK1/2. Blocking the activation of these two pathways by PI3-kinase inhibitor and ERK inhibitor results in the proliferation arresting and migration inhibition.
Previous data showed that OPN increased VEGF expression in breast cancer cells, and induced tumor EC migration and angiogenesis through paracrine and juxtacrine pathways (Chakraborty et al., 2008) . Here we provide evidence that OPN upregulates the expression of VEGF in HUVECs directly. The phosphorylation of Akt and ERK is undetectable in HUVECs under low serum growth supplement condition, and OPN is the only initial stimulation factor at the beginning. OPN binds to its receptor avb3, which is highly expressed on the surface of HUVECs, and induces Akt and ERK phosphorylation. The expression of CD44, another receptor of OPN, is almost undetectable in HUVECs. Anti-avb3 integrin or anti-OPN antibody can completely block the interaction between OPN and avb3, and consequently inhibits the phosphorylation of Akt and ERK in the early time phase (30 min), as shown in Figures 2d and 4a . Several studies have indicated that VEGF stimulates EC proliferation and migration by mediating activation of ERK and Akt (Kilic et al., 2006 , Solorzano et al., 2001 . In addition, anti-VEGF antibody could only block the activation of AKT and ERK 24 h after OPN incubation, and has no effect on the phosphorylation at 30 min. These data showed that OPN-induced VEGF involved in the second phase activation of AKT/ERK pathway through the phosphorylation of KDR. These results provide the evidence to support the hypothesis that OPN stimulates PI3K, Akt and ERK phosphorylation in HUVECs, and the increased VEGF production also induces PI3K, Akt and ERK activation. VEGF is critical for HUVEC proliferation and tube formation. Anti-VEGF antibody can efficiently block angiogenesis induced by VEGF (Asano et al., 1995) . Although anti-VEGF antibody could partially inhibit the migration and tube formation of HUVECs induced by OPN in vitro, the anti-OPN antibody 1A12 was a more efficient inhibitor. These results suggest that OPN simulates HUVECs directly through a VEGF-independent pathway and that VEGF acts only as a positive feedback signal.
In this study, the strong OPN-induced angiogenesis observed in vitro were further confirmed by in vivo experiments. We found that OPN directly stimulated various ECs, including chicken, rabbit and mouse, which are associated with microvessel formation in vivo. The anti-OPN antibody 1A12 is more effective than that of anti-VEGF antibody on the OPN-induced neovessel formation, suggesting that VEGF partially participates in the process of OPN-induced angiogenesis. In accord with the involvement of OPN in regulating new blood vessel formation, overexpression of OPN enhanced tumor neovascularization in a MCF-7 xenograft model. Anti-OPN antibody 1A12 inhibits angiogenesis in tumor through inducing the apoptosis of ECs just as anti-VEGF antibody does. MVD in anti-OPN 1A12-treated tumors decreased significantly compared not only to control tumors, but also to anti-VEGF-treated tumors, indicating that anti-OPN 1A12 has the therapeutic potential for those anti-VEGF-resistant and OPN-overexpressed tumors. To the best of our knowledge, this is the first report showing that anti-OPN 1A12 inhibits the angiogenesis On day 8, gelatin sponges loaded with OPN, vascular endothelial growth factor (VEGF) or phosphate-buffered saline (PBS) were applied to the chicken CAM, and their effects on vascular development were evaluated 4 days later. In some groups, anti-OPN antibody 1A12 or anti-VEGF antibody (1 mg) was added simultaneously with OPN to examine its ability to inhibit the OPN-induced angiogenic response. The angiogenesis response was evaluated as the number of vessels converging toward the gelatin sponge. Neovascularization was marked by black arrows. Experiments were repeated three times, with a minimum of eight embryos in each treatment group. In summary, we provide direct evidence that OPN enhances angiogenesis through the PI3K/AKT-and ERK-mediated pathway with VEGF acting as a positive feedback signal, thus contributing to tumor angiogenesis in vivo. OPN might serve as a potential target for antiangiogenic therapy.
Materials and methods
Animals, cell lines, antibodies and proteins Four-to six-week-old female nude mice and BALB/c mice were purchased from Animal Center of Chinese Academy of Sciences. HUVECs were purchased from Cascade Biologics (Portland, OR, USA) and grown in the Medium 200 supplemented with low serum growth supplement. The rabbit polyclonal anti-PI3K, AKT, ERK1/2, FAK, KDR, actin; mouse monoclonal anti-phospho-PI3K, AKT, ERK1/2, FAK, KDR, Bcl-xL, Bax, VEGF and anti-avb3 integrin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). LYZ94002 and PD98059 were obtained from Calbiochem (San Diego, CA, USA). Gene encoding human OPN was cloned from MDA-MB-435s cells and expressed in yeast vector pPICZaA. Recombinant OPN protein was purified and stored in À20 1C for use. Human breast cancer cell line, MCF-7, was obtained from ATCC (Manassas, VA, USA) and was transfected with OPN cDNA in pcDNA3.1 or with an empty pcDNA3.1 using Lipofectmine 2000 (Invitrogen, Carlsbad, CA, USA).
Generation of anti-OPN monoclonal antibody
Mouse lymphoma cells, NS-1, were fused with spleen cells from BALB/c mice that were immunized by recombinant human OPN (rhOPN). Positive clone 1A12 was screened and confirmed by enzyme-linked immunosorbent assay. BALB/c mice were inoculated intraperitoneally with 1A12 hybridoma cells, and anti-OPN antibody 1A12 was purified from ascitic fluids using a protein-G-Sepharose column (Pharmacia, Uppsala, Sweden). Western blotting gives the evidence that anti-human OPN antibody 1A12 can crossreact with mice OPN (data not shown). Mouse immunoglobulin (IgG) was also prepared from ascitic fluids from mouse plasmacytoma and used as control.
HUVEC proliferation assay
Human umbilical vein endothelial cells were seeded at 2 Â 10 4 cells per well in 96-well plates and allowed to adhere overnight before experimentation. HUVECs were serum-starved, and pretreated with or without LY294002 (10 mM), PD980592 (30 mM), anti-avb3 antibody (20 ug/ml), anti-OPN antibody 1A12 (20 mg/ml) or anti-VEGF antibody (20 mg/ml), respectively or together and stimulated by OPN (5 mM) for 24 h. Then 1 mCi per well 3 H-thymidine was added and incubated for an additional 6 h at 37 1C. Cells were washed, fixed with 10% trichloroacetic acid and counted. All assays were performed in triplicates and repeated for three times.
HUVEC apoptosis assay
Apoptosis was induced in HUVECs by serum deprivation as described earlier (Khan et al., 2002) . To determine the apoptosis of HUVECs, HUVECs were seeded at a density of 2 Â 10 5 cells per well in six-well plates and cultured in complete medium for 24 h. The cells were then incubated with OPN (5 mM) with or without anti-OPN antibody 1A12 (5 mM) for 24 h. The cells were stained with fluorescein isothiocyanateconjugated annexin V/PI and analysed by flow cytometry. The extent of the apoptosis was quantified as a percentage of annexin V-positive cells.
Cell migration assay
Cell invasion was measured by 24-well Transwell system with polycarbonate filters of 8 mm pore size. The upper side was coated with Matrigel. After rehydration, 5 Â 10 5 HUVECs were pretreated with or without LY294002 (10 mM), PD980592 (30 mM), anti-avb3 antibody (20 mg/ml), anti-OPN antibody 1A12 (20 mg/ml) or anti-VEGF antibody (20 mg/ml), respectively or together and stimulated by OPN (5 mM). After 24 h of incubation, the non-migrating cells on the upper side of the filter were scraped and washed. The migrating cells on the reverse side of the filter were stained with crystal violet. The migrating cells on the filter were counted and photomicrographs were taken under an Olympus inverted microscope (Lake Success, NY, USA).
Capillary tube formation of HUVECs
Capillary tube formation by HUVECs was assayed as described earlier (Nishiyama et al., 2005) . Briefly, 100 ml of Matrigel thawed on ice overnight was added to each well of a 96-well plate. After polymerization of the gel, 2 Â 10 4 of HUVECs were plated onto the gel in Medium 200. In some wells, OPN with or without LY294002 (10 mM), PD980592 (30 mM), anti-avb3 antibody (20 mg/ml), anti-OPN antibody 1A12 (20 mg/ml) or anti-VEGF antibody (20 mg/ml), respectively or together were added to the cells at the time of incubation. Capillary tube formation was assessed after 8 h using an inverted microscope (Leica, Deerfield, IL, USA) fitted with a Coolsnap digital camera (Photometrics, Tucson, AZ, USA). To quantify tube formation, three random areas were imaged and the length of cordlike structures (defined as those exceeding 200 mm in length) was measured using Open Lab software (Improvision, Coventry, UK).
Electrophoretic mobility shift assay
The DNA activity of NF-kB was determined by electrophoretic mobility shift assay. A double-stranded oligonucleotide containing the DNA-binding site for the NF-kB proteins (forward: 5 0 -AGTTGAGGGGACTTTCCCAGGC-3 0 , reverse: 5 0 -GCCT GGGAAAGTCCCCTCAACT-3 0 ) was end-labeled using biotin. HUVECs were treated with OPN with or without LY294002 (10 mM), PD980592 (30 mM) and anti-OPN antibody 1A12 (20 mg/ml) for 6 h. Nuclear proteins were extracted with NE-PER nuclear and cytoplasmic extraction reagents (Pierce, Rockford, IL, USA). The nuclear extracts (3 mg) were incubated with 20 fmol of biotin-labeled double-stranded NF-kB oligonucleotide in binding buffer. The DNA-binding complex was resolved on a native polyacrylamide gel and analysed.
Immunoprecipitation and western blotting Human umbilical vein endothelial cells were pretreated with the various concentrations of OPN for different time intervals and then lysed with lysis buffer. PI3K p85a was immunoprecipitated from the supernatant using anti-PI3K p85a antibodies for 1 h, then protein-G PLUS-Sepharose was added for 1 h. The pelleted protein-G-Sepharose was washed with 1 ml Trissaline buffer and eluted with Laemmli SDS reducing buffer.
The immunoprecipitates or HUVEC lysates were separated by SDS-polyacrylamide gel electrophoresis using 8% gels and transferred to polyvinylidene difluoride membranes. After probing with individual antibodies, antigen-antibody complex was visualized by enhanced chemiluminescence's reagents Supersignal (Pierce).
Reverse-transcription-PCR analysis
Total RNA of the cells treated as described above was isolated using the RNeasy mini kit (Qiagen, Hilden, Germany), and genomic DNA was removed using the RNase-Free DNase set (Promega, Madison, WI, USA). First-strand cDNA was generated using the Reverse Transcription System kit (Promega). For quantification of integrin and VEGF mRNA expression, real-time PCR was carried out as described earlier (Xu et al., 2005) .
Chicken embryo CAM assay Gelatin sponge was supplemented with the following: (a) vehicle in phosphate-buffered saline alone, (b) VEGF (200 ng, positive control), (c) OPN (200 ng), (d) OPN and control Ig, (e) OPN and anti-VEGF (1 mg) and (f) OPN and anti-OPN (1 mg). The CAM of chicken eggs was added with 1-mm 3 sterilized gelatin sponges on day 8. At day 12, CAM was photographed in ovo with a stereomicroscope equipped with a digital camera. The angiogenetic responses were evaluated as the number of vessels converging toward the gelatin sponge.
Rabbit corneal micropocket assay Slow-release hydron/sucralfate pellets were prepared by mixing aliquots of OPN/sucralfate solution with anti-OPN or anti-VEGF antibody. New Zealand white rabbits were anesthetized and topical anesthesia was applied to the corneal surface. A 3-mm incision was made in the center of the cornea, and a micropocket was created in the cornea stroma, which extended 1 mm away from the limbus. The pellets with contents described above were inserted into the corneal stromal pocket. Representative slit lamp photographs of rabbit corneas were taken on day 7 after implantation.
Xenografted tumors in nude mice and assessment of vessel density Female nude mice (4-6 weeks of age) were anesthetized and a single incision laterally across the abdomen was made to reveal the fourth mammary gland. MCF-7 cells (5 Â 10 6 cells/100ml), with or without OPN transfection, were injected into the cleared mammary fat pad (six mice per group). A 0.72 mg E2 pellet (Innovative Research, Sarasota, FL, USA) was implanted subcutaneously on the dorsal side of each mouse to support the growth of the estrogen-dependent MCF-7 cell-derived tumors (Brady et al., 2002) . For antibody treatment, 1A12 or anti-VEGF antibody (400 mg/kg of body weight) was injected to the site of tumor twice a week up to 6 weeks. After 6 weeks, mice were killed and tumors were excised.
To evaluate tumor vessel density, anti-CD31 antibody was used to identify capillary-sized vessels in frozen sections of primary tumors. The tumor sections were incubated with rat anti-mouse CD31 overnight at 4 1C. After washing with phosphate-buffered saline, the slides were incubated with goat anti-rat antibody conjugated to phycoerythrin for 1 h. Areas with relatively high vascular density, commonly referred to as hot spots, were identified microscopically. CD31-positive vessels in these areas were counted in three separate fields at a magnification of Â 200 (or 0.74 mm 2 ). The mean value was calculated, and MVD was expressed as the number of vessels per square millimeter (Weidner, 1995) .
For immunofluorescence double staining of CD31/terminal deoxynucleotidyl transferase-mediated nick end labeling, CD31 staining for MVD was performed as described above. After washed with phosphate-buffered saline, terminal deoxynucleotidyl transferase-mediated nick end labeling staining was performed using a commercially available apoptosis detection kit (Dead End Fluorometric TUNEL System, Promega). These sections were fluorescently observed by microscopic LSM system (Carl Zeiss Co. Ltd, Tokyo, Japan).
Statistical methods
The data were analysed using the unpaired t-test with twotailed P-value or analysis of variance (for multiple comparisons) to calculate the statistical significance between control group and treated groups. The results are presented as means ± s.e. of the mean. Statistically significant differences were defined as having a Po0.05.
